Multi Drug Resistant Organisms
6
1
1
4
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 6 trials
100.0%
+13.5% vs benchmark
0%
0 trials in Phase 3/4
25%
1 of 4 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 4 completed trials
Clinical Trials (6)
Characterization of the Synergistic Antibacterial Effect of Verapamil on Bacterial Isolates From Cancer Patients
Infection Risk Associated With Digestive MDRO Carriage in Hospitalized Patients
Derivation and Validation of the Risk Evaluation Score for Pneumonia Involving Resistant Entities (RESPIRE)
Establishment of the Human Intestinal and Salivary Microbiota Biobank - Gastrointestinal Diseases
Prevention of Nosocomial Infections (CleanKids)
Active Bathing to Eliminate Infection (ABATE Infection) Trial